# Adial Pharmaceuticals, Inc.: financial statements, quarterly

ADIL · Nasdaq · CIK 1513525 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/adil.md) · [Financials](/companies/adil/financials.md) · [Filings](/companies/adil/filings.md) · [Insiders](/companies/adil/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/adil/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [0.2](/filings/0001213900-24-097519.md) | [0.3 d](/filings/0001213900-25-019771.md) | [0.5](/filings/0001213900-25-043281.md) | [1.0](/filings/0001213900-25-075695.md) | [1.0](/filings/0001213900-25-109979.md) | [0.7 d](/filings/0001213900-26-024175.md) | [0.7](/filings/0001213900-26-053907.md) | [0.7](/filings/0001213900-26-111121.md) | [0.5](/filings/0001213900-25-109979.md) | [0.6 d](/filings/0001213900-26-024175.md) | [0.4](/filings/0001213900-26-053907.md) | [0.4](/filings/0001213900-26-111121.md) |
| Operating income | $m | [(1.4)](/filings/0001213900-24-097519.md) | [(1.8) d](/filings/0001213900-25-019771.md) | [(1.8)](/filings/0001213900-25-043281.md) | [(2.3)](/filings/0001213900-25-075695.md) | [(2.2)](/filings/0001213900-25-109979.md) | [(1.9) d](/filings/0001213900-26-024175.md) | [(2.3)](/filings/0001213900-26-053907.md) | [(1.9)](/filings/0001213900-26-111121.md) | [(1.8)](/filings/0001213900-25-109979.md) | [(1.9) d](/filings/0001213900-26-024175.md) | [(2.0)](/filings/0001213900-26-053907.md) | [(52.0)](/filings/0001213900-26-111121.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(1.4)](/filings/0001213900-24-097519.md) | [(1.9) d](/filings/0001213900-25-019771.md) | [(6.5)](/filings/0001213900-25-109979.md) | [(2.5)](/filings/0001213900-25-109979.md) | [(2.2)](/filings/0001213900-25-109979.md) | [(2.1) d](/filings/0001213900-26-024175.md) | [(2.2)](/filings/0001213900-26-111121.md) | [(2.0)](/filings/0001213900-26-111121.md) | [(1.8)](/filings/0001213900-25-109979.md) | [(2.0) d](/filings/0001213900-26-024175.md) | [(2.0)](/filings/0001213900-26-111121.md) | [(52.0)](/filings/0001213900-26-111121.md) |
| Diluted EPS | $ per share | [(1.18)](/filings/0001213900-24-097519.md) | not reported | [(2.19)](/filings/0001213900-25-043281.md) | [(0.59)](/filings/0001213900-25-075695.md) | [(0.38)](/filings/0001213900-25-109979.md) | not reported | [(8.52)](/filings/0001213900-26-053907.md) | [(4.61)](/filings/0001213900-26-111121.md) | [(0.08)](/filings/0001213900-25-109979.md) | not reported | [(1.48)](/filings/0001213900-26-053907.md) | [(11.25)](/filings/0001213900-26-111121.md) |
| Basic EPS | $ per share | [(1.18)](/filings/0001213900-24-097519.md) | not reported | [(2.19)](/filings/0001213900-25-043281.md) | [(0.59)](/filings/0001213900-25-075695.md) | [(0.38)](/filings/0001213900-25-109979.md) | not reported | [(8.52)](/filings/0001213900-26-053907.md) | [(4.61)](/filings/0001213900-26-111121.md) | [(0.08)](/filings/0001213900-25-109979.md) | not reported | [(1.48)](/filings/0001213900-26-053907.md) | [(11.25)](/filings/0001213900-26-111121.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.3](/filings/0001213900-23-086913.md) | [2.8](/filings/0001213900-25-019771.md) | not reported | [3.3](/filings/0001213900-24-068262.md) | [5.2](/filings/0001213900-24-097519.md) | [3.8](/filings/0001213900-26-024175.md) | [2.4](/filings/0001213900-25-043281.md) | [5.9](/filings/0001213900-25-075695.md) | [4.6](/filings/0001213900-25-109979.md) | [5.9](/filings/0001213900-26-024175.md) | not reported | not reported |
| Current assets | $m | [1.1](/filings/0001213900-23-086913.md) | [3.2](/filings/0001213900-25-019771.md) | not reported | [3.8](/filings/0001213900-24-068262.md) | [5.6](/filings/0001213900-24-097519.md) | [4.1](/filings/0001213900-26-024175.md) | [2.6](/filings/0001213900-25-043281.md) | [6.1](/filings/0001213900-25-075695.md) | [5.0](/filings/0001213900-25-109979.md) | [6.2](/filings/0001213900-26-111121.md) | [4.8](/filings/0001213900-26-053907.md) | [28.8](/filings/0001213900-26-111121.md) |
| Total assets | $m | [2.9](/filings/0001213900-23-086913.md) | [4.7](/filings/0001213900-25-019771.md) | not reported | [4.9](/filings/0001213900-24-068262.md) | [6.7](/filings/0001213900-24-097519.md) | [5.0](/filings/0001213900-26-024175.md) | [3.5](/filings/0001213900-25-043281.md) | [6.8](/filings/0001213900-25-075695.md) | [5.7](/filings/0001213900-25-109979.md) | [6.7](/filings/0001213900-26-111121.md) | [5.2](/filings/0001213900-26-053907.md) | [29.1](/filings/0001213900-26-111121.md) |
| Current liabilities | $m | [0.5](/filings/0001213900-23-086913.md) | [0.7](/filings/0001213900-25-019771.md) | not reported | [0.7](/filings/0001213900-24-068262.md) | [0.8](/filings/0001213900-24-097519.md) | [1.0](/filings/0001213900-26-024175.md) | [1.3](/filings/0001213900-25-043281.md) | [1.2](/filings/0001213900-25-075695.md) | [1.2](/filings/0001213900-25-109979.md) | [1.4](/filings/0001213900-26-111121.md) | [1.5](/filings/0001213900-26-053907.md) | [5.1](/filings/0001213900-26-111121.md) |
| Total liabilities | $m | [0.5](/filings/0001213900-23-086913.md) | [0.7](/filings/0001213900-25-019771.md) | not reported | [0.7](/filings/0001213900-24-068262.md) | [0.8](/filings/0001213900-24-097519.md) | [1.0](/filings/0001213900-26-024175.md) | [1.3](/filings/0001213900-25-043281.md) | [1.2](/filings/0001213900-25-075695.md) | [1.2](/filings/0001213900-25-109979.md) | [1.4](/filings/0001213900-26-111121.md) | [1.5](/filings/0001213900-26-053907.md) | [28.9](/filings/0001213900-26-111121.md) |
| Shareholders' equity | $m | [2.3](/filings/0001213900-24-097519.md) | [4.1](/filings/0001213900-26-024175.md) | [6.1](/filings/0001213900-25-109979.md) | [4.3](/filings/0001213900-25-109979.md) | [5.9](/filings/0001213900-25-109979.md) | [4.1](/filings/0001213900-26-111121.md) | [2.1](/filings/0001213900-26-111121.md) | [5.6](/filings/0001213900-26-111121.md) | [4.5](/filings/0001213900-25-109979.md) | [5.3](/filings/0001213900-26-111121.md) | [3.7](/filings/0001213900-26-111121.md) | [(38.4)](/filings/0001213900-26-111121.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,391) d](/filings/0001213900-24-097519.md) | [(1,223) d](/filings/0001213900-25-019771.md) | [(1,626)](/filings/0001213900-25-043281.md) | [(2,148) d](/filings/0001213900-25-075695.md) | [(1,694) d](/filings/0001213900-25-109979.md) | [(1,454) d](/filings/0001213900-26-024175.md) | [(1,585)](/filings/0001213900-26-053907.md) | [(1,750) d](/filings/0001213900-26-111121.md) | [(1,833) d](/filings/0001213900-25-109979.md) | [(1,325) d](/filings/0001213900-26-024175.md) | [(1,612)](/filings/0001213900-26-053907.md) | [(6,363) d](/filings/0001213900-26-111121.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | [0.0 d](/filings/0001213900-25-019771.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.0](/filings/0001213900-23-086913.md) | [26.5](/filings/0001213900-23-038985.md) | [1.1](/filings/0001213900-24-068262.md) | [1.2](/filings/0001213900-24-097519.md) | [3.0](/filings/0001213900-25-043281.md) | [4.2](/filings/0001213900-25-075695.md) | [5.8](/filings/0001213900-25-109979.md) | [0.3](/filings/0001213900-26-053907.md) | [0.4](/filings/0001213900-26-111121.md) | [22.2](/filings/0001213900-25-109979.md) | [1.4](/filings/0001213900-26-053907.md) | [4.6](/filings/0001213900-26-111121.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,625,890 at 2026-08-12, from the cover of the [10-Q/A filed 2026-10-21](/filings/0001213900-26-111121.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.